tiprankstipranks
Advertisement
Advertisement

Cannara Biotech Posts Solid Q2, Becomes Top Cannabis Retailer in Québec

Story Highlights
  • Cannara Biotech delivered profitable Q2 2026 results, generating solid revenues, margins and operating cash flow while continuing to invest in capacity for future growth.
  • The company expanded its national retail presence and secured the number one cannabis retail market share in Québec, strengthening its competitive position in Canada.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Cannara Biotech Posts Solid Q2, Becomes Top Cannabis Retailer in Québec

Claim 30% Off TipRanks

Cannara Biotech ( (TSE:LOVE) ) just unveiled an update.

Cannara Biotech reported Q2 fiscal 2026 results showing continued profitability and strong cash generation, with total net revenues of $27.2 million, gross profit before fair value adjustments of $11.6 million, adjusted EBITDA of $6.0 million and operating cash flow of $2.9 million. Management highlighted that, despite typical post-holiday seasonal softness and normalization of vape sales in Québec, the company’s brands continued to perform well and support investment in its Valleyfield facility to underpin future growth.

The company expanded its estimated national retail market share to 4.4% in Q2 2026, up from 4.1% in the prior quarter, driven largely by strength in Québec and gains in provinces such as British Columbia while maintaining stability in Ontario. Cannara also reached the number one retail sales market share position in Québec with an estimated 14.3% share, reinforcing its competitive positioning in the provincial cannabis market and signaling stronger influence in the broader Canadian cannabis landscape.

The most recent analyst rating on (TSE:LOVE) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Cannara Biotech stock, see the TSE:LOVE Stock Forecast page.

Spark’s Take on LOVE Stock

According to Spark, TipRanks’ AI Analyst, LOVE is a Neutral.

The score is driven primarily by solid financial performance—healthy margins, steady revenue growth, and improving leverage—offset by weaker/less consistent free cash flow. Technicals are mixed with neutral momentum and slight short-term softness, while valuation appears reasonable based on the P/E.

To see Spark’s full report on LOVE stock, click here.

More about Cannara Biotech

Cannara Biotech Inc. is a vertically integrated Canadian cannabis producer specializing in premium-grade products at affordable prices, operating two large-scale facilities in Québec totaling over 1.6 million square feet. Listed on the TSX, OTCQX and Frankfurt exchanges, the company focuses on retail cannabis markets across Canada, with a particularly strong presence in Québec and growing penetration in other key provinces.

Average Trading Volume: 44,562

Technical Sentiment Signal: Buy

Current Market Cap: C$190.6M

For a thorough assessment of LOVE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1